Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.05 USD
Change Today +0.0022 / 4.86%
Volume 4.1M
AMBS On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

amarantus bioscience holding (AMBS) Snapshot

Open
$0.05
Previous Close
$0.05
Day High
$0.05
Day Low
$0.05
52 Week High
07/29/14 - $0.20
52 Week Low
04/7/15 - $0.03
Market Cap
49.5M
Average Volume 10 Days
2.6M
EPS TTM
$-0.03
Shares Outstanding
1.0B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AMARANTUS BIOSCIENCE HOLDING (AMBS)

Related News

No related news articles were found.

amarantus bioscience holding (AMBS) Related Businessweek News

No Related Businessweek News Found

amarantus bioscience holding (AMBS) Details

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostics and therapeutics for the treatment of Alzheimer's disease, Parkinson's disease, and ophthalmological disorders. The company’s diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer’s disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with relapsing-remitting multiple sclerosis at first clinical presentation. Its therapeutic products in development comprise Eltoprazine, a small molecule drug that is in Phase II clinical trials for the treatment of Parkinson’s disease Levadopa-Induced Dyskinesia and adult attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including iretinitis pigmentosa, Parkinson’s disease, cardiac ischemia, and stroke. It is also developing NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson’s disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus Bioscience Holdings, Inc. in April 2013. Amarantus Bioscience Holdings, Inc. was founded in 2008 and is based in San Francisco, California.

10 Employees
Last Reported Date: 04/6/15
Founded in 2008

amarantus bioscience holding (AMBS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $230.1K
Vice President of Financial Operations, Corpo...
Total Annual Compensation: $261.0K
Chief Scientific Officer, Director and Member...
Total Annual Compensation: $213.8K
Compensation as of Fiscal Year 2013.

amarantus bioscience holding (AMBS) Key Developments

Amarantus Bioscience Holdings, Inc, Q4 2014 Earnings Call, Apr 09, 2015

Amarantus Bioscience Holdings, Inc, Q4 2014 Earnings Call, Apr 09, 2015

Amarantus Bioscience Holdings, Inc. Reports Consolidated Financial Results for the Year Ended December 31, 2014

Amarantus Bioscience Holdings Inc. reported consolidated financial results for the year ended December 31, 2014. For the period, the company's loss from operations was $21,354,000 compared to $5,711,000 a year ago. Net loss attributable to common stockholders was $28,152,000 or $0.04 per basic and diluted share compared to $15,170,000 or $0.03 per basic and diluted share a year ago.

Amarantus Bioscience Holdings, Inc Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-07-2015 10:30 AM

Amarantus Bioscience Holdings, Inc Presents at 10th Annual Neurotech Investing & Partnering Conference, Apr-07-2015 10:30 AM. Venue: Hotel Nikko, 222 Mason Street, San Francisco, California, United States. Speakers: Gerald E. Commissiong, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AMBS:US $0.05 USD +0.0022

AMBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AMBS.
View Industry Companies
 

Industry Analysis

AMBS

Industry Average

Valuation AMBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AMARANTUS BIOSCIENCE HOLDING, please visit www.amarantus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.